Has Caio Max Rocha Lima, MD received payments from drug or device companies?

Yes. Drug and device makers reported $109,534 in general payments to Caio Max Rocha Lima, MD across 127 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Caio Max Rocha Lima, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Caio Max Rocha Lima, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Caio Max Rocha Lima, MD

Hematology & Oncology · Winston Salem, NCNPI 1023040094

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $72,061 of the $109,534 with a category attached, or 65.8%. 15 manufacturers reported payments, led by Eisai Inc. at 40.2% of the total. Reporting peaked in 2019 at $88,503 and has fallen 96.1% since, to $3,487 in 2025. Among hematology & oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$109,534in general payments, 2019–2025

Across 127 payments — averaging $862.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eisai Inc.$44K
Merck$22K
Bristol Myers Squibb$14K
Incyte Corporation$11K
Taiho Oncology, Inc.$7K
Ipsen Biopharmaceuticals, Inc$4K
plus $9K from 9 others

$2,513,438in research payments, 2019–2025

Across 234 payments — averaging $10,741 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$1.5M
Genentech, Inc.$692K
Merck$112K
Incyte Corporation$102K
AstraZeneca$38K
Seagen Inc.$36K
plus $63K from 4 others

What the payments were for

Consulting fees$15,78514%
Speaking & faculty fees$72,06166%
Travel & lodging$18,64817%
Food & beverage$2,9433%
Education$970%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eisai Inc.	54	$44,076
Merck	20	$21,723
Bristol Myers Squibb	12	$13,777
Incyte Corporation	19	$10,670
Taiho Oncology, Inc.	4	$6,576
Ipsen Biopharmaceuticals, Inc	2	$4,170
Agios Pharmaceuticals, Inc.	5	$4,017
Jazz Pharmaceuticals Inc.	1	$3,296
Exelixis Inc.	2	$478
AstraZeneca	3	$344
Genentech USA, Inc.	1	$115
Gilead	1	$102
Astellas Pharma US Inc	1	$75
Genentech, Inc.	1	$70
Amgen	1	$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LENVIMA$43,336
KEYTRUDA$21,441
Abraxane$13,711
Lonsurf$6,490
TIBSOVO$3,936
ZIIHERA$3,296
SOMATULINE DEPOT$2,800
ONIVYDE$1,370
Cabometyx$456
IMFINZI$116
TECENTRIQ$115
Trodelvy$102

How this compares

$109,534 in reported general payments places this provider in the 90th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$37,430

Medicare patients

109

Services billed

319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CreonLipase/Protease/Amylase	16	$36,084
Ursodiol	14	$874
Pantoprazole Sodium	11	$386
Prochlorperazine Maleate	14	$187
Potassium Chloride	16	$172
Ondansetron Hcl	19	$160
Lidocaine-PrilocaineLidocaine/Prilocaine	12	$154
Ondansetron OdtOndansetron	14	$139

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Winston Salem

Angela AlistarWinston Salem$509K
Ravi PaluriWinston Salem$314K
Timothy PardeeWinston Salem$68K
Leon Bernal-MizrachiWinston Salem$62K
Matthew WieduwiltWinston Salem$36K
John McKayWinston Salem$22K
Amit MehtaCary$4.3M
Michael MorseDurham$2.6M
Shelbi AtrashCharlotte$994K
Phillip FebboDurham$749K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →